Credit Suisse’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-35,734
Closed -$2.15M 4770
2021
Q1
$2.15M Buy
+35,734
New +$1.29M ﹤0.01% 2766

Credit Suisse's PAND Position: Q2 2021 in Review

Credit Suisse sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 35,734 shares — an estimated $2.15M sold.

Credit Suisse first reported a position in PAND in Q1 2021 and held it in 1 quarter. The position peaked at $2.15M in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • Credit Suisse reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Credit Suisse sold 35,734 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $2.15M.
  • Credit Suisse first reported a position in Pandion Therapeutics Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Credit Suisse's Pandion Therapeutics Inc. Common Stock position peaked at $2.15M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.